David Enloe, Jr, formerly Introgen’s senior vice president of operations, has been named president and CEO of the company, succeeding Mr Nance, who will continue in his role as chairman of the board.
As a result of the restructuring, Introgen’s non-manufacturing operations will be significantly reduced and will principally support the Advexin regulatory programs in the US and Europe.
In addition to David Nance, Max Talbott, senior vice president of clinical affairs, Robert Sobol, senior vice president of medical and scientific affairs, and David Parker, senior vice president of intellectual property have resigned their positions as officers of Introgen as a further step to preserve financial resources. However, to best support program continuity, these former officers, as well as other senior regulatory and medical staff, will continue to be available to the company through consulting or other arrangements.